Michael Weir

Representative experience includes advising:

• Spectra Medical Devices LLC, a portfolio company of QHP Capital, on its acquisition of XL Precision Technologies, a Contract Development and Manufacturing Organization specializing in the manufacture of precision micro-components, complex tubular components, and sub-assemblies for the medical device industry.
• Lanes Group Limited, one of the UK's leading providers of water and wastewater services, and its shareholders on its acquisition by funds managed by Global Infrastructure Partners (GIP), a part of BlackRock.
• Summit Partners and other shareholders, including management, on the sale of CluePoints SA to EQT. CluePoints is a provider of AI-based software for risk-based monitoring and data quality oversight of clinical trial studies.
• Nordic Capital and management on the sale of the ADVANZ PHARMA Group by Nordic Capital to: (a) Nordic Capital's Fund XI (continuation fund); and (b) Ontario Teachers' Pension Plan (OTPP).
• Oaktree Capital Management and Cornerstone Investment Management on their sale of Avenga, a software engineering and consulting services provider, to KKCG, a Czech private investment group.
• Bregal Milestone and other shareholders on the sale of Epassi Group Oy, a leading pan-European platform for digital employee benefit payments, including meals, transportation, healthcare, exercise, and culture, to a consortium consisting of TA Associates and Warburg Pincus.
• Clinigen (a Triton portfolio company) on multiple transactions including:
  • the sale of Lamda Laboratories to Adragos Pharma; 
  • the £167m sale of Proleukin to Iovance Biotherapeutics; and 
  • the disposal of a portfolio of cancer support products to CNX Therapeutics;
• Karo Kealthcare (an EQT portfolio company) on the $235m acquisition of Lamisil from Haleon;
• Evidia (an EQT portfolio company) on the acquisition of 4ways;
• Advanz Pharma on a number of transactions including: 
  • the $846m acquisition of Advanz by Nordic Capital;
  • the acquisition of Correvio Pharm Corp; and 
  • the $450m acquisition of the non-US business of Intercept Pharmaceuticals.
• Triton on:
  • the acquisition of OCU Group Limited, a leading UK multi-utility services specialist operating within regulated infrastructure; and
  • its investment in Wavelynx Technologies, a leader in the field of secure and open mobile-first identity and access control solutions;
• Nordic Capital on the sale of Veonet.
• Ober Scharrer Gruppe (a Nordic Capital portfolio company) on the acquisition from CBPE Capital of UK eye surgery group SpaMedica;
• An investment consortium led by CVC Capital Partners in connection with the acquisition from the Recordati family of the holding company that owns a 51.8 percent stake in the Italian pharmaceutical group Recordati for approximately €3 billion (US$3.5 billion)
• Alvogen (a CVC portfolio company) on a range of matters
• Care Capital (one of the largest global investors in the dental sector) on the acquisition of Neoss, a manufacturer of dental implants
• Medcaptain Medical Technology on the acquisition from BTL Medical Technology of Penlon (a UK headquartered medical device manufacturer)
• The founders of Novalpina Capital in connection with its restructuring and liquidation
• Bud Financial on its Series A and Series B financing rounds;
• Regnology (a Nordic Capital portfolio company) on the acquisition of Vizor Software;
• Neighborly (a KKR portfolio company) on the acquisition of Pimlico Plumbers;
• Novator on the $425m disposal of CCP Games (the developer of EVE Online) to Pearl Abyss;
• Atlas Mara, Standard Trust Bank and the other selling shareholders on the sale of Union Bank of Nigeria plc to Titan Trust Bank;
• Management of Itiviti on sale to Broadridge.
• Management of Calastone on sale to Carlyle.
• Management of IFS and Workwave in connection with the sale by EQT of a controlling stake to Hg.
• Founders and management of Titan Wealth on the acquisition of a majority stake by Parthenon.